ACAD (ACADIA Pharmaceuticals) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


ACAD ACADIA Pharmaceuticals Inc ACAD
76 GF Score
Price $23.36
GF Value $25.02
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

ACADIA Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ACAD vs EWTX, CRNX, VKTX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


ACAD
76GF Score
ACADIA Pharmaceuticals Inc ACAD
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of $23.36 is trading 6.6% below its estimated GF Value™ of $25.02. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for ACAD:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $25.02 vs. price of $23.36 (6.6% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:MexicoDR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for ACAD

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.36
Price
$25.02
GF Value